Immunosuppression in Lung Transplantation

Joelle Nelson, Elisabeth Kincaide, Jamie Schulte, Reed Hall, Deborah Jo Levine

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Immunosuppression in lung transplantation is an area devoid of robust clinical data. This chapter will review the history of immunosuppression in lung transplantation. Additionally, it will evaluate the three classes of induction, maintenance, and rescue immunosuppression in detail. Induction immunosuppression in lung transplantation aims to decrease incidence of lung allograft rejection, however infectious risk must be considered when determining if induction is appropriate and which agent is most favorable. Similar to other solid organ transplant patient populations, a multi-drug approach is commonly prescribed for maintenance immunosuppression to minimize single agent drug toxicities. Emphasis of this review is placed on key medication considerations including dosing, adverse effects, and drug interactions. Clinical considerations will be reviewed per drug class given available literature. Finally, acute cellular, antibody mediated, and chronic rejection are reviewed.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
PublisherSpringer Science and Business Media Deutschland GmbH
Pages139-164
Number of pages26
DOIs
StatePublished - 2022

Publication series

NameHandbook of Experimental Pharmacology
Volume272
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Keywords

  • CLAD
  • Immunosuppression
  • Lung transplant

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint

Dive into the research topics of 'Immunosuppression in Lung Transplantation'. Together they form a unique fingerprint.

Cite this